Immunovant Sciences GmbH   Report issue

For profit Phase 2
Founded: Basel Switzerland (2018)

Organization Overview

First Clinical Trial
2019
NCT03922321
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Immunovant Sciences GmbH